Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
FDA Approves Pfizer’s BeneFIX® 3,000 IU Dosage
 

Pfizer Hemophilia recently announced that the U.S. Food and Drug Administration approved the 3,000 IU dosage strength of BeneFIX®, a recombinant factor IX product indicated for the control, prevention and peri-operative management of bleeding episodes in adult and pediatric patients with hemophilia B.

 

According to Pfizer, the new dosage option will be available to patients in the coming months. Pfizer Hemophilia is the first to offer this new dosage strength for hemophilia B patients, providing reconstitution convenience for those taking 3,000 IU or higher dosage strengths.

 

Source: Pfizer